$AIMMay 27, 2026, 12:47 PMAI processed
AIM says Ampligen gave 100% survival in USAMRIID mouse Ebola study; investor video planned
AI Summary
AIM ImmunoTech announced an on-demand investor presentation (June 4) highlighting previously published USAMRIID BSL‐4 preclinical data showing Ampligen (rintatolimod) produced 100% survival when administered early in a lethal mouse Ebola model at 6 mg/kg. The company cited the WHO PHEIC for the Bundibugyo outbreak and highlighted Ampligen's TLR3 mechanism and prior orphan-drug designations, but these results are preclinical, no human Ebola trials or approvals were announced, and human efficacy remains unproven.
Positives
- Published USAMRIID BSL‑4 preclinical study reported 100% survival in mice with early Ampligen treatment
- Protective dose in mice was 6 mg/kg, a dose the company says is generally well-tolerated in humans
- Ampligen has prior Orphan Drug designation for Ebola from FDA and EMA
Negatives
- Results are preclinical (mouse model) and do not demonstrate efficacy in humans
- No new human trials, regulatory filings, or emergency authorizations for Ebola were announced
- Company is promoting an investor video rather than disclosing new clinical or partnership commitments